Alyssa Klee
About
Research
Publications
2023
Novel Antimurine Thyroid-Stimulating Hormone Receptor Monoclonal Antibodies
Klee A, Torchia J, Freeman G. Novel Antimurine Thyroid-Stimulating Hormone Receptor Monoclonal Antibodies. Monoclonal Antibodies In Immunodiagnosis And Immunotherapy 2023, 42: 109-114. PMID: 37343169, PMCID: PMC10282802, DOI: 10.1089/mab.2022.0037.Peer-Reviewed Original ResearchConceptsThyroid-stimulating hormoneAnti-TSHR autoantibodiesThyroid-stimulating hormone receptorGraves' diseaseHashimoto's thyroiditisThyroid diseaseG protein-coupled receptorsMonoclonal antibodiesAnti-TSHR antibodiesReceptor monoclonal antibodyProduction of thyroxineImmune attackMouse modelAgonist activityAberrant productionThyroid hormonesAutoantibodiesDiseaseHormone receptorsAntibodiesThyroiditisThyroid proteinsThyroidHormoneRange of affinities
2022
A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
Bu M, Yuan L, Klee A, Freeman G. A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. Monoclonal Antibodies In Immunodiagnosis And Immunotherapy 2022, 41: 202-209. PMID: 35925787, PMCID: PMC9451140, DOI: 10.1089/mab.2021.0068.Peer-Reviewed Original ResearchConceptsPD-1Cancer immunotherapyMouse modelPD-L1 monoclonal antibodiesPD-L1/PDMonoclonal antibodiesEffective cancer immunotherapyAntibody effector activityMouse PD-1Murine PD-1PD-L1Novel agentsEffector activityTherapeutic monoclonal antibodiesImmunotherapyEpitope recognitionMAbsAntibodiesHigh affinityBlockadePathwayBiological activity
2021
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
Bhatt R, Berjis A, Konge J, Mahoney K, Klee A, Freeman S, Chen C, Jegede O, Catalano P, Pignon J, Sticco-Ivins M, Zhu B, Hua P, Soden J, Zhu J, McDermott D, Arulanandam A, Signoretti S, Freeman G. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunology Research 2021, 9: 156-169. PMID: 33229411, PMCID: PMC8284010, DOI: 10.1158/2326-6066.cir-20-0315.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaTumor immune evasionImmune evasionInhibitory receptorsT cellsKiller cell immunoglobulin-like receptorsImmune inhibitory pathwaysCell renal cell carcinomaNatural killer cellsImmunoglobulin-like receptorsRenal cell carcinomaImmune inhibitory activityImmunoinhibitory pathwayImmunoregulatory ligandsRelated SpotlightPDL1 expressionKiller cellsPD1 pathwayHHLA2 expressionCell carcinomaB7 familyCostimulatory effectCostimulatory signalsEffective cancer therapyHHLA2
2018
PD-L1 binds to B7-1 only in cis on the same cell surface
Chaudhri A, Xiao Y, Klee A, Wang X, Zhu B, Freeman G. PD-L1 binds to B7-1 only in cis on the same cell surface. Cancer Immunology Research 2018, 6: canimm.0316.2017. PMID: 29871885, PMCID: PMC7394266, DOI: 10.1158/2326-6066.cir-17-0316.Peer-Reviewed Original ResearchConceptsPD-L1PD-1B7-1Tumor-infiltrating myeloid cellsB7-1 interactionPD-L1 bindsSoluble PD-1Death ligand 1T cell functionPD-L1 bindingPeripheral toleranceTumor immunotherapyCancer immunotherapyCell binding assaysImmune attackMyeloid cellsSame cellsSuch coexpressionSame cell surfaceLigand 1ImmunotherapyCD28Further investigationELISACytometry